Cargando…
Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes
BACKGROUND: We report prospectively captured clinical toxicity and patient reported outcomes in a single institutional cohort of patients treated for prostate cancer with proton beam therapy (PBT). This is the largest reported series of patients treated mostly with pencil beam scanning PBT. METHODS:...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142310/ https://www.ncbi.nlm.nih.gov/pubmed/30223877 http://dx.doi.org/10.1186/s13014-018-1127-6 |
_version_ | 1783355831048208384 |
---|---|
author | Lee, Howard J. Macomber, Meghan W. Spraker, Matthew B. Bowen, Stephen R. Hippe, Daniel S. Fung, Angela Russell, Kenneth J. Laramore, George E. Rengan, Ramesh Liao, Jay Apisarnthanarax, Smith Zeng, Jing |
author_facet | Lee, Howard J. Macomber, Meghan W. Spraker, Matthew B. Bowen, Stephen R. Hippe, Daniel S. Fung, Angela Russell, Kenneth J. Laramore, George E. Rengan, Ramesh Liao, Jay Apisarnthanarax, Smith Zeng, Jing |
author_sort | Lee, Howard J. |
collection | PubMed |
description | BACKGROUND: We report prospectively captured clinical toxicity and patient reported outcomes in a single institutional cohort of patients treated for prostate cancer with proton beam therapy (PBT). This is the largest reported series of patients treated mostly with pencil beam scanning PBT. METHODS: We reviewed 231 patients treated on an IRB approved institutional registry from 2013 to 2016; final analysis included 192 patients with > 1-year of follow-up. Toxicity incidence was prospectively captured and scored using CTCAE v4.0. International Prostate Symptoms Score (IPSS), Sexual Health Inventory for Men (SHIM) score, and Expanded Prostate Cancer Index Composite (EPIC) bowel domain questionnaires were collected at each visit. Univariate Cox regression was used to explore associations of grade 2+ toxicity with clinical, treatment, and dosimetric variables. RESULTS: Median follow-up was 1.7 years. Grade 3 toxicity was seen in 5/192 patients. No grade 4 or 5 toxicity was seen. Patient reported quality-of-life showed no change in urinary function post-radiation by IPSS scores. Median SHIM scores declined by 3.7 points at 1-year post-treatment without further decrease beyond year 1. On univariate analysis, only younger age (HR = 0.61, p = 0.022) was associated with decreased sexual toxicity. EPIC bowel domain scores declined from 96 at baseline (median) by an average of 5.4 points at 1-year post-treatment (95% CI: 2.5–8.2 points, p < 0.001), with no further decrease over time. Bowel toxicity was mostly in the form of transient rectal bleeding and was associated with anticoagulation use (HR = 3.45, p = 0.002). CONCLUSIONS: Grade 3 or higher toxicity was rare at 2-years after treatment with PBT for localized prostate cancer. Longer follow-up is needed to further characterize late toxicity and biochemical control. TRIAL REGISTRATION: NCT, NCT01255748. Registered 1 January 2013. |
format | Online Article Text |
id | pubmed-6142310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-61423102018-09-20 Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes Lee, Howard J. Macomber, Meghan W. Spraker, Matthew B. Bowen, Stephen R. Hippe, Daniel S. Fung, Angela Russell, Kenneth J. Laramore, George E. Rengan, Ramesh Liao, Jay Apisarnthanarax, Smith Zeng, Jing Radiat Oncol Research BACKGROUND: We report prospectively captured clinical toxicity and patient reported outcomes in a single institutional cohort of patients treated for prostate cancer with proton beam therapy (PBT). This is the largest reported series of patients treated mostly with pencil beam scanning PBT. METHODS: We reviewed 231 patients treated on an IRB approved institutional registry from 2013 to 2016; final analysis included 192 patients with > 1-year of follow-up. Toxicity incidence was prospectively captured and scored using CTCAE v4.0. International Prostate Symptoms Score (IPSS), Sexual Health Inventory for Men (SHIM) score, and Expanded Prostate Cancer Index Composite (EPIC) bowel domain questionnaires were collected at each visit. Univariate Cox regression was used to explore associations of grade 2+ toxicity with clinical, treatment, and dosimetric variables. RESULTS: Median follow-up was 1.7 years. Grade 3 toxicity was seen in 5/192 patients. No grade 4 or 5 toxicity was seen. Patient reported quality-of-life showed no change in urinary function post-radiation by IPSS scores. Median SHIM scores declined by 3.7 points at 1-year post-treatment without further decrease beyond year 1. On univariate analysis, only younger age (HR = 0.61, p = 0.022) was associated with decreased sexual toxicity. EPIC bowel domain scores declined from 96 at baseline (median) by an average of 5.4 points at 1-year post-treatment (95% CI: 2.5–8.2 points, p < 0.001), with no further decrease over time. Bowel toxicity was mostly in the form of transient rectal bleeding and was associated with anticoagulation use (HR = 3.45, p = 0.002). CONCLUSIONS: Grade 3 or higher toxicity was rare at 2-years after treatment with PBT for localized prostate cancer. Longer follow-up is needed to further characterize late toxicity and biochemical control. TRIAL REGISTRATION: NCT, NCT01255748. Registered 1 January 2013. BioMed Central 2018-09-17 /pmc/articles/PMC6142310/ /pubmed/30223877 http://dx.doi.org/10.1186/s13014-018-1127-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Lee, Howard J. Macomber, Meghan W. Spraker, Matthew B. Bowen, Stephen R. Hippe, Daniel S. Fung, Angela Russell, Kenneth J. Laramore, George E. Rengan, Ramesh Liao, Jay Apisarnthanarax, Smith Zeng, Jing Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes |
title | Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes |
title_full | Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes |
title_fullStr | Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes |
title_full_unstemmed | Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes |
title_short | Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes |
title_sort | early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142310/ https://www.ncbi.nlm.nih.gov/pubmed/30223877 http://dx.doi.org/10.1186/s13014-018-1127-6 |
work_keys_str_mv | AT leehowardj earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes AT macombermeghanw earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes AT sprakermatthewb earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes AT bowenstephenr earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes AT hippedaniels earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes AT fungangela earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes AT russellkennethj earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes AT laramoregeorgee earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes AT renganramesh earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes AT liaojay earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes AT apisarnthanaraxsmith earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes AT zengjing earlytoxicityandpatientreportedqualityoflifeinpatientsreceivingprotontherapyforlocalizedprostatecancerasingleinstitutionalreviewofprospectivelyrecordedoutcomes |